Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.61 |
| ▸ | OGFRL1 | Q5TC84 | 11/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977285 | 0.87 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2436917 | 0.86 | OPRM1 (0.66) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL14040921 | 0.85 | OPRM1 (0.57) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2437055 | 0.85 | OPRM1 (0.65) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2437119 | 0.84 | OPRM1 (0.64) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL13473615 | 0.81 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2976864 | 0.80 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2437087 | 0.80 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL2973500 | 0.79 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2973808 | 0.79 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260042-B1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-09-21 | — | — | EP | claimed |
| US-8293758-B2 | Substituted spirocyclic cyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-2260042-B1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20090247561-A1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247561-A1 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OGFRL1 5/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.